BES meeting 2022 (Final program)

Final program

32th Meeting of the Belgian Endocrine Society
October 21 & 22, 2022

(Mdeon visa: 22/V2/10413/008299)

Friday symposia 21-10-2022

14:00 Registration
14:30-15:45 Symposium 1 (sponsored by Ipsen)
Chair: Guy T’Sjoen (UGhent)
Part 1: Highlights of ECE 

  • Focus on neuroendocrine tumors
    Wouter de Herder (NL, Erasmus MC, Amsterdam)
  • Focus on acromegaly
    Albert Beckers (ULiège)

Part 2: Innovation for patients with patients
           Mrs S. Llahana (UK, University College of London)

Part 3: Discussion/Q&A

15:45-16:00 Pauze
16:00-17:15 Symposium 2 (sponsored by Lilly)
A new chapter on incretin development

  • Welcome and introduction
    André Scheen (chair, Belgium)
  • What we have learned in almost two decades of incretin treatment16:05-16:15
    André Scheen (chair, Belgium)
  • GIP and GLP-1, the twin-cretin hormones: Similarities and differences. 16:15-16:35
    Michael Nauck (Germany)
  • Novel dual incretin receptor agonists: surpassing standards in diabetes care. 16:35-16:55
    Christophe De Block (Belgium)
  • Panel discussion and audience key questions on data presented  16:55-17:10
  • Summary and consolidation
    André Scheen (chair, Belgium)
17:15–17:50 Coffee
17:50–18:00 Welcome
B. Velkeniers (VUB), President
18:00–20:00 Symposium: a message from three young emeriti 
Chair: P. Petrossians (ULiège)     

  • How do they grow so tall ?
    Albert Beckers (ULiège)
  • A 2022 update in the management of prolactinoma.
    Dominique Maiter (UCL)
  • Immune checkpoint inhibitors and endocrine side effects.
    Brigitte Velkeniers (VUB)
20:00 Walking dinner

Saturday meeting 22-10-2022

8:00–8:30 Registration
Coffee, visit of the exhibits, poster view
8:30–8:50 General assembly
B. Velkeniers (VUB), President
8:50-9:00 Introduction of BSED and EYES
Inge Van Boxelaer (BSED)
Jonathan Mertens (EYES)
9:00–9:30 Clinical grand-round: hypoparathyroidism
Introduced by O. Alexopoulou (UCL)

Brigitte Decallone (KUL) & Bernard Corvilain (ULB)
9:30-11:00 Communications by young investigators
(sponsored by Pfizer)
9:30–10:30 Part 1: Clinical and translational studies
Chair: L. Crenier (ULB)

  • Exercise as a non-pharmacological intervention to protect pancreatic beta cells in patients with type 1 and type 2 diabetes.
    Alexandra Coomans de Brachène (ULB)
  • A plasma miR-193b-365 signature predicts non-responsiveness to Lactococcus lactis-based antigen-specific immunotherapy in new-onset type 1 diabetes.
    Grabriele Sassi (KUL)
  • The insulin sensitivity index derived from euglycemic clamps is correlated to liver fat content determined by magnetic resonance spectroscopy in type 1 diabetes .
    Jonathan Mertens (UA)
  • Mortality-related risk factors of inpatients with diabetes and COVID-19: a multicentric retrospective study in Belgium
    Thomas Servais (UCL)
10:30–11:00 Part 2: Clinical case reports
Chair: M. Bex (KUL)

  • Chromosome 22q11.2 deletion syndrome revealed by severe hypocalcemia and pulseless electric activity: Untangling a conglomerate of potential primary etiologic factors.
    Eric Balti (VITAZ St. Niklaas)
  • Is this just vitiligo? Nelson is hiding.
    Maarten De Vis (VUB)
11:00–11:45 Coffee break, visit of the exhibits and poster view
11:45–12:00 Selected Belgian Publication Award (sponsored by Sandoz)
Introduced by C. De Block (UA)  
Margaretha Visser et al. The Lancet 2021; 397:2275-2283
Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial.

Presenting author: Margaretha Visser (KUL)
12:00–12:30 Belgian Endocrine Society Lecture Award (sponsored by Novo)
Introduced by B. Velkeniers (VUB), President  
Determinants and consequences of sex steroid exposure in men.
Award winner: Bruno Lapauw (UGhent)
12:30–13:00 Invited lecture
Chair: Patrick Petrossians (Uliège)  
Menopauze – 20 years after WHI (Women’s Health Initiative).
Axelle Pintiaux (ULiège)
13:00–13:15 Award ceremony of the young investigators
13:15 Lunch